AC Immune SA

General Information

We are a clinical stage biopharmaceutical company leveraging our two proprietary technology platforms to discover, design and develop novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases associated with protein misfolding. Misfolded proteins are generally recognized as the leading cause of neurodegenerative diseases, such as Alzheimer’s disease, or AD, and Parkinson’s disease, or PD, with common mechanisms and drug targets, such as Abeta, tau and alpha-synuclein.

Employees: 62
Founded: 2003
Contact Information
Address EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland
Phone Number +41 21 693 91 21
Web Address
View Prospectus: AC Immune SA
Financial Information
Market Cap $664.8mil
Revenues $45.1 mil (last 12 months)
Net Income $21.4 mil (last 12 months)
IPO Profile
Symbol ACIU
Exchange NASDAQ
Shares (millions): 6.0
Price range $11.00 - $11.00
Est. $ Volume $66.0 mil
Manager / Joint Managers Credit Suisse/ Jefferies/ Leerink Partners
CO-Managers -
Expected To Trade: 9/23/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change